<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70472">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01871441</url>
  </required_header>
  <id_info>
    <org_study_id>13D.127</org_study_id>
    <secondary_id>2012-104</secondary_id>
    <nct_id>NCT01871441</nct_id>
  </id_info>
  <brief_title>Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies</brief_title>
  <official_title>A Two Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation for Patients in Remission From HLA Partially-Matched Related Donors-Effect of Maternal Donors on Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well haploidentical donor hematopoietic stem cell transplant
      works in treating patients with hematologic malignancies. Giving chemotherapy and total-body
      irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It
      may also stop the patient's immune system from rejecting the donor's stem cells. Giving an
      infusion of the donor's T cells (donor lymphocyte infusion) may replace the patient's immune
      cells and help destroy any remaining cancer cells. When the stem cells from a related donor,
      that closely matches the patient's blood, are infused into the patient they may help the
      patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Examine the 1 year disease free survival (DFS) rate of patients with maternal donors or
      sibling donors who share the maternal haplotype (maternal group) and compare them to
      patients receiving cells from donors who have points from other characteristics such as
      killer immunoglobulin-like receptor (KIR) ligand mismatching, minor histocompatibility
      antigen (MHag) differences, or number of human leukocyte antigen (HLA) mismatches
      (non-maternal group).

      SECONDARY OBJECTIVES:

      I. Assess the incidences of relapse and graft-versus-host disease (GVHD) in maternal
      recipients whose only eligible donors are offspring.

      II. Assess the incidence of grades III-IV GVHD in female recipients with male donors.

      III. Compare the rates of DFS in recipient-donor combinations in which there is at least 1
      KIR ligand mismatch versus those without a KIR ligand mismatch.

      OUTLINE:

      Patients undergo total body irradiation (TBI) twice daily (BID) on days -9 to -6, undergo
      donor lymphocyte infusion (DLI) on day -6, and receive cyclophosphamide intravenously (IV)
      over 2 hours on days -3 and -2.

      TRANSPLANT: Patients undergo haploidentical allogeneic hematopoietic stem cell transplant on
      day 0.

      GVHD PROPHYLAXIS: Patients receive tacrolimus IV beginning on day -1 with taper beginning on
      day 42, and mycophenolate mofetil IV BID from day -1 to day 28.

      After completion of study treatment, patients are followed up at 90, 180, and 270 days, and
      1 year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as the time to death, relapse or disease progression. The difference in DFS between maternal and non-maternal groups will be tested using log-rank test. The survival curves for each group will be estimated using the Kaplan-Meier estimator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of relapse and GVHD in maternal recipients whose only eligible donors are offspring</measure>
    <time_frame>Up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rates of relapse and GVHD in maternal recipients whose only eligible donors are offspring will be computed with corresponding exact binomial 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of grade III-IV GVHD in female recipients with male donors</measure>
    <time_frame>Up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The rates of grade III-IV GVHD in female recipients with male donors will be computed with corresponding exact binomial 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rates of grade III-IV GVHD in female recipients with male donors will be computed with corresponding exact binomial 95% confidence intervals.</measure>
    <time_frame>Up to 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The difference in DFS in recipient-donor combinations in which there is at least 1 KIR ligand mismatch versus those without a KIR ligand mismatch will be tested using log-rank test.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment (haploidentical allogeneic HSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo TBI BID on days -9 to -6, undergo DLI on day -6, and receive cyclophosphamide IV over 2 hours on days -3 and -2.
TRANSPLANT: Patients undergo haploidentical allogeneic hematopoietic stem cell transplant on day 0.
GVHD PROPHYLAXIS: Patients receive tacrolimus IV beginning on day -1 with taper beginning on day 42, and mycophenolate mofetil IV BID from day -1 to day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-body irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (haploidentical allogeneic HSCT)</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Donor lymphocytes infusion (DLI)</intervention_name>
    <description>Undergo DLI</description>
    <arm_group_label>Treatment (haploidentical allogeneic HSCT)</arm_group_label>
    <other_name>Allogeneic Lymphocytes</other_name>
    <other_name>ALLOLYMPH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (haploidentical allogeneic HSCT)</arm_group_label>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>cytophosphane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic hematopoietic stem cell transplantation (HSCT)</intervention_name>
    <description>Undergo haploidentical allogeneic HSCT</description>
    <arm_group_label>Treatment (haploidentical allogeneic HSCT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (haploidentical allogeneic HSCT)</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>fujimycin</other_name>
    <other_name>Prograf</other_name>
    <other_name>Advagraf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (haploidentical allogeneic HSCT)</arm_group_label>
    <other_name>CellCept</other_name>
    <other_name>Myfortic</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any patient with a hematologic or oncologic diagnosis without morphological evidence
             of disease in which allogeneic HSCT is thought to be beneficial.

          2. Patients must have a related donor who is a two or more allele mismatch at the HLA-A;
             B; C; DR loci.

          3. Patients must have adequate organ function:

               1. LVEF (Left ventricular ejection fraction) of &gt;50%

               2. Diffusion Capacity for Carbon Monoxide (DLCO) &gt;50% of predicted corrected for
                  hemoglobin

               3. Adequate liver function as defined by a serum bilirubin &lt;1.8, Aspartate
                  Aminotransferase (AST) or alanine aminotransferase (ALT) &lt; 2.5X upper limit of
                  normal

               4. Creatinine clearance of &gt; 60 ml/min

          4. Performance status &gt; 80% (TJU Karnofsky)

          5. Hematopoietic Comorbidity Index (HCT-CI) Score &lt; 5 Points

          6. Patients must be willing to use contraception if they have childbearing potential

          7. Able to give informed consent, or if decisionally impaired, have a legal next of kin
             or guardian that can give informed consent

        Exclusion Criteria:

          1. Performance status &lt; 80 % (TJU Karnofsky)

          2. HCT-CI Score &gt; 5 Points

          3. Combination of Performance status of &lt; 80% (TJU Karnofsky) and an HCT-CI of 4 points
             or more.

          4. HIV positive

          5. Active involvement of the central nervous system with malignancy

          6. Psychiatric disorder that would preclude patients from signing an informed consent

          7. Pregnancy

          8. Patients with life expectancy of &lt; 6 months for reasons other than their underlying
             hematologic/oncologic disorder

          9. Patients who have received alemtuzumab within 8 weeks of the transplant admission, or
             who have recently received horse or rabbit anti-thymocyte globulin and have an ATG
             level of &gt; 2 ugm/ml

         10. Patients who cannot receive cyclophosphamide

         11. Patients with evidence of another malignancy, exclusive of a skin cancer that
             requires only local treatment, should not be enrolled on this protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dolores Grosso, DNP, CRNP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dolores Grosso, DNP, CRNP</last_name>
    <phone>215-955-0182</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donna Zuccarello</last_name>
    <phone>215-955-6612</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dolores Grosso, DNP, CRNP</last_name>
    </contact>
    <contact_backup>
      <last_name>Donna Zuccarello</last_name>
      <phone>215-955-6612</phone>
    </contact_backup>
    <investigator>
      <last_name>Dolores Grosso, DNP, CRNP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Neal Flomenberg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>S. Onder Alpdogan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Carabasi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joanne Filicko-O'Hara, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ubaldo Martinez-Outschoorn, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Wagner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Weiss, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://www.JeffersonHospital.org</url>
    <description>Thomas Jefferson University Hospitals</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 13, 2013</lastchanged_date>
  <firstreceived_date>June 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
